Cart
sales@molnova.com
SR9243
CAS No. 1613028-81-1
SR9243( SR9243 | SR-9243 | SR 9243. )
Catalog No. M12335 CAS No. 1613028-81-1
SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 119 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 296 | In Stock |
|
| 200MG | 477 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSR9243
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR9243 is a LXR inverse agonist that induces LXR-corepressor interaction.
-
DescriptionSR9243 is a LXR inverse agonist that induces LXR-corepressor interaction; shows anticancer activity and selectively targets the warburg effect and lipogenesis.
-
In Vitro——
-
In Vivo——
-
SynonymsSR9243 | SR-9243 | SR 9243.
-
PathwayNuclear Receptor/Transcription Factor
-
TargetLXR
-
RecptorLXR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1613028-81-1
-
Formula Weight626.62
-
Molecular FormulaC31H32BrNO4S2
-
Purity>98% (HPLC)
-
SolubilityDMF: 98 mg/mL warming (156.39 mM)
-
SMILESO=S(C1=C(C)C=C(C)C=C1C)(N(CCC2=CC=CC(Br)=C2)CC3=CC=C(C4=CC=CC(S(=O)(C)=O)=C4)C=C3)=O
-
Chemical NameN-(3-bromophenethyl)-2,4,6-trimethyl-N-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Flaveny CA, et al. Y Cell. 2015 Jun 24. pii: S1535-6108(15)00183-X.
molnova catalog
related products
-
GW3965
A potent, selective, orally active LXR agonist that recruits the steroid receptor coactivator 1 to human LXRα in a cell-free ligand-sensing assay with an EC50 of 125 nM.
-
BMS-779788
A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ.
-
BMS-852927
A novel potent, partial LXRβ-selective agonist (EC50=9 nM) with 20% LXRα and 88% LXRβ activity compared to a full pan agonist in transactivation assays.
